Modifying geriatric chemotherapy regimens improves quality of life without reducing treatment efficacy, according to a study. Modified regimens reduced toxicity and functional decline while maintaining efficiency.
Traditional chemotherapy may impair older cancer patients, according to a JAMA Network Open study. Leading researchers at the University of Rochester Medical Center’s Wilmot Cancer Institute showed that changing geriatric chemotherapy regimens improves quality of life without harming efficacy.
In the countrywide clinical trial GAP70+, Drs. Mostafa R. Mohamed, MD, PhD, and Supriya G. Mohile, MD, MS, studied approximately 600 70-year-olds. Reduced doses and schedules helped almost 30% of patients avoid dangerous side effects.
Modified chemotherapy patients had 15% fewer serious side effects than traditional chemotherapy patients. They cut patient-reported functional decline 20%. The modifications did not affect treatment efficacy because 32% fewer adverse events occurred.
The study underscores the necessity for personalized treatment for elderly advanced cancer patients with associated health concerns. Deviating from standards and tailoring chemotherapy for older patients can improve treatment plans and outcomes.
This study suggests considering age and comorbidities while formulating cancer therapy. It helps doctors adapt and improve cancer treatment for older patients.
Conclusion
Changing chemotherapy regimens for older patients improves quality of life without reducing efficacy, according to a University of Rochester Medical Center Wilmot Cancer Institute study. For nearly 600 70-year-olds, adjusted regimens reduced major toxic effects by 15% and functional impairment by 20%. The study recommends considering age and comorbidities when treating cancer.
